inosine-pranobex and Diabetes-Mellitus--Type-1

inosine-pranobex has been researched along with Diabetes-Mellitus--Type-1* in 3 studies

Reviews

2 review(s) available for inosine-pranobex and Diabetes-Mellitus--Type-1

Article	Year
[The immunotherapy of type-1 diabetes mellitus--experiences, results and prospects]. Vutreshni bolesti, 1990, Volume: 29, Issue:4 Topics: Adrenal Cortex Hormones; Azathioprine; Combined Modality Therapy; Cyclosporins; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Immunotherapy; Inosine Pranobex; Plasmapheresis	1990
[Immunotherapy in type 1 (insulin-dependent) diabetes]. Recenti progressi in medicina, 1984, Volume: 75, Issue:10 Topics: Animals; Bone Marrow Transplantation; Child; Cyclosporins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Humans; Immunosuppressive Agents; Immunotherapy; Inosine Pranobex; Interferon Type I; Levamisole; Plasmapheresis; Prednisone; Rats; Thymectomy	1984

Trials

1 trial(s) available for inosine-pranobex and Diabetes-Mellitus--Type-1

Article	Year
Trial of mild immunosuppression by methisoprinol in acute onset diabetes mellitus: effects on rate and duration of remission. Diabetes research (Edinburgh, Scotland), 1986, Volume: 3, Issue:7 There is a lot of data that suggests the immune system plays a role in the pathogenesis of Type 1 DM. Methisoprinol, an immunomodulatory drug, has been reported as being efficient in preventing DM induced by a low dose of streptozotocin in mice. The efficiency of this drug in Type 1 DM was assessed by the rate and duration of remission obtained in recent acute onset DM by strict blood glucose control. We used 2 different therapeutic procedures successively: one was short in an anti-viral aim (50 mg/kg body wt. daily during 10 days) and the other longer given as immunomodulatory treatment (50 mg/kg body wt. daily during 2 weeks and 30 mg/kg body wt. daily during 4 weeks more) with reinduction (30 mg/kg body wt. daily during 4 weeks) every 5 months. No side effect was observed during the treatment. In both studies there was no improvement in the rate and duration of remission when compared to controls; residual beta-cell function was not increased after treatment by methisoprinol. Mild immunotherapy did not appear helpful in Type 1 DM. Topics: Adolescent; Adult; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Female; Humans; Immunosuppression Therapy; Inosine; Inosine Pranobex; Male; Remission Induction	1986

Article

Year

Trial of mild immunosuppression by methisoprinol in acute onset diabetes mellitus: effects on rate and duration of remission.

Diabetes research (Edinburgh, Scotland), 1986, Volume: 3, Issue:7

There is a lot of data that suggests the immune system plays a role in the pathogenesis of Type 1 DM. Methisoprinol, an immunomodulatory drug, has been reported as being efficient in preventing DM induced by a low dose of streptozotocin in mice. The efficiency of this drug in Type 1 DM was assessed by the rate and duration of remission obtained in recent acute onset DM by strict blood glucose control. We used 2 different therapeutic procedures successively: one was short in an anti-viral aim (50 mg/kg body wt. daily during 10 days) and the other longer given as immunomodulatory treatment (50 mg/kg body wt. daily during 2 weeks and 30 mg/kg body wt. daily during 4 weeks more) with reinduction (30 mg/kg body wt. daily during 4 weeks) every 5 months. No side effect was observed during the treatment. In both studies there was no improvement in the rate and duration of remission when compared to controls; residual beta-cell function was not increased after treatment by methisoprinol. Mild immunotherapy did not appear helpful in Type 1 DM.

Topics: Adolescent; Adult; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Female; Humans; Immunosuppression Therapy; Inosine; Inosine Pranobex; Male; Remission Induction

1986